Navitor is pioneering the development of novel therapeutics for a wide range of diseases by targeting the primary cellular pathway involved in nutrient signaling and regulation of cell growth and function

Publications show all

Navitor Pharmaceuticals has published 1 articles.

SEC Filings show all

D3

Private Funding Events

DateOfferedSoldType
2014-08-15$23,521,560$13,521,560Equity
2014-06-26$23,521,560$13,521,560Equity

Contact Information

    Key Executives

    • Rick Lundberg
      Executive Officer
    • Alan Crane
      Director
    • Jean-Francois Formela
      Director
    • Marian Nakada
      Director
    • Brian Gallagher
      Director
    • George Vlasuk
      Executive Officer, Director